INTRUSION INC (INTZ): Nasdaq/NYSE listing notice — Intrusion receives Nasdaq delisting notice for failing $35M market value requirement

INTRUSION INC

Received Nasdaq Staff Determination on Oct 26, 2023 for non-compliance with $35M MVLS requirement for continued listing.
Plans to request hearing before Nasdaq Hearings Panel, which will stay delisting pending decision.
No immediate effect on trading of INTZ common stock; continues to trade on Nasdaq Capital Market.
Company may seek alternative compliance under Equity Standard (Rule 5550(b)(1)), but no assurance of regaining compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

INTRUSION INC received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

October 26, 2023, Intrusion Inc. (the “Company”) received a letter from the Listing Qualifications Staff of Nasdaq (the "Staff Determination") notifying the Company that, based upon the Company's non-compliance with the $35 million market value of listed securities requirement ("MVLS") for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Marketplace Rule 5550(b)(2), the Company's securities are subject to delisting from Nasdaq unless the Company requests a hearing before a Nasdaq Hearings Panel (the “Hearings Panel"). The Company plans to timely request a hearing before a

View on SEC.gov

8 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

INTRUSION INC filing history →

Source: SEC EDGAR

accession 0001683168-23-007467

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.